Repligen | RGEN - Stock


Repligen reported $186.6M in Stock for its fiscal quarter ending in June of 2026.





Stock Change Date
Agilent USD 1.09B 30M Mar/2026
Align Technology USD 212.24M 2.7M Jun/2026
Bio Techne USD 201.18M 4.27M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Bristol-Myers Squibb USD 2.74B 19M Jun/2026
Bruker USD 1.12B 1.4M Jun/2026
Charles River Laboratories USD 346.26M 13.46M Jun/2026
Danaher USD 3.26B 652M Jun/2026
Dentsply International USD 665M 6M Jun/2026
General Electric Aerospace USD 12.44B 73M Jun/2026
Henry Schein USD 2.06B 45M Jun/2026
Illumina USD 629M 18M Jun/2026
Mettler Toledo International USD 411.56M 6.74M Jun/2026
Myriad Genetics USD 30.6M 2.7M Jun/2026
OraSure Technologies USD 30.31M 753K Mar/2026
Pacific Biosciences Of California USD 61.08M 10.06M Jun/2026
Pfizer USD 9.94B 722M Jun/2026
Repligen USD 186.6M 7.35M Jun/2026
Revvity USD 378.5M 9M Jun/2026
Standard Biotools USD 18.59M 1.39M Mar/2026
Thermo Fisher Scientific USD 5.5B 71M Mar/2026
Waters USD 1.38B 119M Jun/2026
West Pharmaceutical Services USD 447.4M 5.2M Jun/2026